Treatment of Refractory or Resistant CMV
This conference is being held virtually.
Target Audience
This course is intended for pharmacists.
Learning Objectives
At the completion of this activity, the participant will be able to:
- Recognize cytomegalovirus, its prevalence in solid organ transplant and HSCT patients, and standard-of-care treatments associated with prevention and treatment of diseases.
- Evaluate current guidelines and primary literature examining the utilization of letermovir and maribavir for the prevention and treatment of CMV, including refractory and resistant CMV.
- Apply knowledge and design treatment plans for patients who have high-risk refractory or resistant CMV.
Faculty
Karishma Desai, Pharm.D. - PGY-2 Infectious Diseases Resident at Advocate Christ Medical Center
Disclosure
The planner(s) and speaker(s) have indicated that there are no relevant financial relationships with any ineligible companies to disclose.
1 contact hour of continuing pharmacy education (1.00 CEU) is available for pharmacist participants.
Available Credit
- 1.00 Continuing Pharmacy Education (CPE)Aurora Health Care Department of Pharmacy Services is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Price
Click “Take Course” to register for this program.
This conference is being held virtually. A link to the meeting will be provided prior to the event.
Contact the AAH Pharmacy Continuing Education team at AAH-PharmacyCPEsubmission@aah.org if you have any questions or need assistance.